Why the study?
PAH carries significant morbidity and mortality despite optimal medical treatment, and combination therapy may be more effective than monotherapy.
Does sildenafil and ambrisentan combination therapy improve hemodynamics and functional class in patients with pulmonary arterial hypertension (Eisenmenger syndrome and idiopathic PAH)?
Does sildenafil and ambrisentan combination therapy improve hemodynamics and functional class in patients with pulmonary arterial hypertension (Eisenmenger syndrome and idiopathic PAH)?
Upfront combination therapy with sildenafil and ambrisentan safely improves NYHA functional class and mean pulmonary artery pressure in patients with PAH, particularly those with Eisenmenger syndrome.
Supports safe upfront sildenafil-ambrisentan in Eisenmenger PAH; extends limited RCT data but leaves superiority open.
Pulmonary arterial hypertension (PAH) - a complex and progressive disease that carries significant morbidity and mortality despite optimal medical treatment. Combination therapy for PAH can be more effective than monotherapy. The present randomized trial compared the safety and efficacy of sildenafil ambrisentan combination therapy with sildenafil monotherapy. Twenty-two patients of Eisenmenger syndrome and five patients of idiopathic PAH were randomized to two arms. There was a significant improvement in NYHA functional class and mean pulmonary artery pressure, while an insignificant improving trend was observed for 6-min walk distance and oxygen saturation, following the 12 weeks of combination therapy. An upfront combination therapy was found to be safe and effective in the management of PAH patients.
No takes yet. Share an insight, caveat, or question.
Mohammed et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Indian Heart Journal